AstraZeneca's Phase III CASPIAN trial final analysis shows Imfinzi confirmed survival benefit for small cell lung cancer patients Medical Dialogues Bureau21 March 2020 3:30 AM GMTImfinzi confirmed a sustained overall survival benefit in the final analysis of the Phase III CASPIAN trial in 1st-line extensive-stage small cell...
AstraZeneca fails to meet target endpoints in Phase II bladder cancer trial Medical Dialogues Bureau10 March 2020 4:00 AM GMTUSA: The Phase III DANUBE trial for Imfinzi (durvalumab) and Imfinzi plus tremelimumab in unresectable, Stage IV (metastatic) bladder cancer did not...